Synta Pharmaceuticals Corp.
38
0
0
29
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 75/100
15.8%
6 terminated/withdrawn out of 38 trials
82.9%
-3.6% vs industry average
5%
2 trials in Phase 3/4
31%
9 of 29 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (38)
STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer
Role: collaborator
SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)
Role: collaborator
Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer
Role: collaborator
STA-9090(Ganetespib) in Metastatic Ocular Melanoma
Role: collaborator
Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
Role: collaborator
STA-9090 in Patients With Advanced Hepatocellular Cancer
Role: collaborator
A Phase I/II Study of Ganetespib in Combination With Doxorubicin
Role: collaborator
STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma
Role: collaborator
Ganetespib Window of Opportunity Study in Head and Neck Cancers
Role: collaborator
A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
Role: lead
A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)
Role: lead
Phase I Trial of Ganetespib, Capecitabine, and Radiation in Rectal Cancer
Role: collaborator
Clinical and Translational Study of STA-9090
Role: collaborator
Open-label Study of STA-9090 for Patients With Metastatic Breast Cancer
Role: collaborator
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
Role: lead
Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer
Role: lead
A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Role: collaborator
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Role: lead
A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)
Role: lead
A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors
Role: lead